Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06903078 · ClinicalTrials.gov registry record
A Study That Collects Participant Data and Biospecimens to Analyze Pathogenic Exosomes That Mediate Increased Vascular Dementia Risk in Individuals With Herpes Zoster.
A clinical trial of Vascular Dementia and Herpes Zoster (HZ), sponsored by Center for Clinical Studies, Texas.
- Recruiting
- Registry status
- 375
- Enrollment target
- 2
- Study locations
NCT06903078: Recruiting study of Vascular Dementia and Herpes Zoster (HZ), sponsored by Center for Clinical Studies, Texas.
NCT06903078 is a study of Vascular Dementia and Herpes Zoster (HZ) that is actively recruiting participants, run by Center for Clinical Studies, Texas. The registered enrollment target is 375 participants, below the 1,160-participant average among 10 other Vascular Dementia trials with a reported enrollment target (68% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06903078, a study of Vascular Dementia and Herpes Zoster (HZ), is actively recruiting participants, sponsored by Center for Clinical Studies, Texas.
- RECRUITING
- Registry status
- 375 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this observational research study is to study if patients with herpes zoster, also known as Shingles, have a higher risk of vascular dysfunction (problems with blood vessels, including stroke) and vascular dementia (problems with mental decline as a result of decreased blood flow to the brain) compared to patients without herpes zoster. Patients are evaluated based on the group they are assigned too: 1. Herpes Zoster (HZ) Group: individuals presenting with untreated herpes zoster. These participants will have 6 visits: * Day 1 = 1st day presenting to clinic with acute zoster * 7 days post zoster * 1 month after Day 1 * 3 months after Day 1 * 6 months after Day 1 * 12 months after Day 1 2. Control Group: individuals without herpes zoster o Day 1 (only 1 visit will be completed) This study does not have a study medication/device. Standard of care for all patients will be followed.
Primary Outcome
Using mass spectrometry and small RNA sequencing, we will quantify abundance and temporal changes of exosomal proteins and miRNAs associated with vascular dysfunction, inflammation, coagulation, and stroke, then correlate analytes with clinical and laboratory features (anti-VZV IgG titers and IgM, complete blood counts, comprehensive metabolic panel, and aPTT/PT/INR). Enrichment analyses will be conducted on the network of exosomal proteins and miRNAs to uncover pathways and shared analytes asso
Conditions Studied
Study Locations (2)
Texas
- Center for Clinical Studies, LTD. LLP - Houston
- Center for Clinical Studies, LTD. LLP - Webster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2025-02-13 |
| Est. Completion | 2030-08 |
What NCT06903078 shows while recruiting
NCT06903078 is an observational study that tracks outcomes without assigning an intervention. The registered 375 participants enrollment target is mid-sized for trials with a published cap, below the 1,160-participant average among 10 other Vascular Dementia trials with a reported enrollment target (68% lower).
The record links to 2 conditions, with Vascular Dementia appearing as the primary indexed condition, and to 0 interventions.
NCT06903078 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06903078 about?
NCT06903078 is a clinical study titled "A Study That Collects Participant Data and Biospecimens to Analyze Pathogenic Exosomes That Mediate Increased Vascular Dementia Risk in Individuals With Herpes Zoster.". The purpose of this observational research study is to study if patients with herpes zoster, also known as Shingles, have a higher risk of vascular dysfunction (problems with blood vessels, including stroke) and vascular dementia (problems with mental decline as a result of decreased blood flow to t...
What is the current status of trial NCT06903078?
This trial is currently recruiting. The enrollment target is 375 participants. The study started on 2025-02-13. Estimated completion is 2030-08.
What conditions does trial NCT06903078 study?
This clinical trial studies the following conditions: Vascular Dementia, Herpes Zoster (HZ).
Who is sponsoring clinical trial NCT06903078?
This trial is sponsored by Center for Clinical Studies, Texas, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06903078 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vascular Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06903078's enrollment target sits among peer trials
375 3rd of 10 higher than 8 of 10 other Vascular Dementia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Vascular Dementia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Longitudinal Cognitive Assessment by BoCA
RECRUITING
-
Pulsed Electromagnetic Field Treatment With Dementia Patients
RECRUITING · NA
-
Cognitive and Vascular Functioning Following TBI
RECRUITING
-
The BRAIN App (Phase 2 SBIR)
RECRUITING · NA
-
Florida Cerebrovascular Disease Biorepository and Genomics Center
ACTIVE NOT RECRUITING
-
Telehealth-enabled Integrated Palliative Care for People With Dementia
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI